Research programme: cancer immunotherapeutics - PsiOxus Therapeutics

Drug Profile

Research programme: cancer immunotherapeutics - PsiOxus Therapeutics

Alternative Names: AbEnAds; anti-human VEGF armed EnAd; anti-PDL1 AbEnAds; NG 345; NG 347; NG 350a; NG 600; NG aEpCAM; NG aFAP; NG-600 series

Latest Information Update: 18 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PsiOxus Therapeutics
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Oncolytic viruses
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epithelial cell adhesion molecule inhibitors; Fibroblast activation protein antagonists; Immunomodulators; Immunostimulants; Programmed cell death-1 ligand-1inhibitors; Vascular endothelial growth factors modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 18 Jul 2017 PsiOxus Therapeutics plans a phase I trial for NG 600 for Cancer (PsiOxus pipeline, January 2017).
  • 14 Apr 2016 PsiOxus Therapeutics and Parker Institute for Cancer enter into a memorandum of understaing for an anticipated collaboration using the Tumor-Specific Immuno-Gene Therapy (T-SIGn) platform developed by PsiOxus Therapeutics for Cancer
  • 15 Oct 2015 Preclinical development for Solid tumours in United Kingdom (intratumoural) before October 2015 (PsiOxus pipeline, October 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top